静脉甲泼尼龙冲击治疗重症COVID-19肺炎:双盲随机安慰剂对照试验
这项多中心双盲随机安慰剂对照试验纳入304例住院COVID-19肺炎患者,在标准地塞米松基础上比较静脉甲泼尼龙1g连续三日冲击治疗与安慰剂。结果显示两组30天内无氧出院比例、中位出院时间、有创通气或死亡风险及总死亡率均无显著差异,严重不良事件发生频率相似,提示加用甲泼尼龙冲击治疗无获益。
要点
- 在标准地塞米松基础上加用甲泼尼龙1g×3天冲击治疗未缩短住院时间。
- 冲击治疗组与安慰剂组有创通气或死亡风险及总死亡率均无显著差异。
- 两组严重不良事件发生频率相似,未观察到额外安全性信号。
核心结论
- 在标准地塞米松治疗基础上加用静脉甲泼尼龙冲击治疗对COVID-19肺炎住院患者无获益。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验,纳入304例住院COVID-19肺炎患者。
- 患者随机接受静脉甲泼尼龙1g连续三日或安慰剂,均联合标准地塞米松治疗。
- 主要终点为随机化至无需补充氧气的出院时间。
主要发现
- 甲泼尼龙组151例中112例(75.4%)与安慰剂组150例中111例(75.2%)在随机化后30天内无氧出院。
- 中位出院时间两组相似:甲泼尼龙组15天(95%CI 13.0-17.0),安慰剂组16天(95%CI 13.8-18.2),HR 0.92(95%CI 0.71-1.20),p=0.528。
- 入住ICU需有创气管插管或死亡:甲泼尼龙组20.0% vs 安慰剂组16.1%,HR 1.26(95%CI 0.74-2.16),p=0.176。
- 总死亡率:甲泼尼龙组10.0% vs 安慰剂组12.2%,HR 0.83(95%CI 0.42-1.64),p=0.584。
- 两组严重不良事件发生频率相似。
关键数值与推荐
- 主要终点无显著差异:HR 0.92(95%CI 0.71-1.20),p=0.528。
- 有创通气或死亡复合终点无显著差异:HR 1.26(95%CI 0.74-2.16),p=0.176。
- 总死亡率无显著差异:HR 0.83(95%CI 0.42-1.64),p=0.584。
临床怎么用
- 对住院COVID-19肺炎患者,不建议在标准地塞米松基础上常规加用静脉甲泼尼龙冲击治疗。
- 临床决策应权衡个体化获益与证据显示的无获益结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Pulse glucocorticoid therapy is used in hyperinflammation related to coronavirus disease 2019 (COVID-19). We evaluated the efficacy and safety of pulse intravenous methylprednisolone in addition to standard treatment in COVID-19 pneumonia. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, 304 hospitalised patients with COVID-19 pneumonia were randomised to receive 1 g of methylprednisolone intravenously for three consecutive days or placebo in addition to standard dexamethasone. The primary outcome was the duration of patient hospitalisation, calculated as the time interval between randomisation and hospital discharge without the need for supplementary oxygen. The key secondary outcomes were survival free from invasive ventilation with orotracheal intubation and overall survival. RESULTS: Overall, 112 (75.4%) out of 151 patients in the pulse methylprednisolone arm and 111 (75.2%) of 150 in the placebo arm were discharged from hospital without oxygen within 30 days from randomisation. Median time to discharge was similar in both groups (15 days, 95% CI 13.0-17.0 days and 16 days, 95% CI 13.8-18.2 days, respectively; hazard ratio (HR) 0.92, 95% CI 0.71-1.20; p=0.528). No significant differences between pulse methylprednisolone and placebo arms were observed in terms of admission to intensive care unit with orotracheal intubation or death (20.0% versus 16.1%; HR 1.26, 95% CI 0.74-2.16; p=0.176) or overall mortality (10.0% versus 12.2%; HR 0.83, 95% CI 0.42-1.64; p=0.584). Serious adverse events occurred with similar frequency in the two groups. CONCLUSIONS: Methylprenisolone pulse therapy added to dexamethasone was not of benefit in patients with COVID-19 pneumonia.
引用
- Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2022. PMID: 35361632. doi:10.1183/13993003.00025-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。